Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Capital Expenditures (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Capital Expenditures for 6 consecutive years, with $32000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Capital Expenditures fell 92.1% year-over-year to $32000.0, compared with a TTM value of -$577000.0 through Sep 2025, down 225.16%, and an annual FY2023 reading of $5.4 million, up 868.34% over the prior year.
  • Capital Expenditures was $32000.0 for Q2 2025 at Barinthus Biotherapeutics, up from $5000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $3.8 million in Q3 2022 and bottomed at -$5.0 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $397500.0, with a median of $165000.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 2894.53% in 2022, while the deepest fall reached 1277.59% in 2022.
  • Year by year, Capital Expenditures stood at $424000.0 in 2021, then plummeted by 1277.59% to -$5.0 million in 2022, then surged by 96.94% to -$153000.0 in 2023, then tumbled by 301.31% to -$614000.0 in 2024, then soared by 105.21% to $32000.0 in 2025.
  • Business Quant data shows Capital Expenditures for BRNS at $32000.0 in Q2 2025, $5000.0 in Q1 2025, and -$614000.0 in Q4 2024.